Search for: "Sandoz, Inc. " Results 21 - 40 of 598
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Jul 2014, 12:08 pm by Morse, Barnes-Brown Pendleton
The reference product, Neupogen®, which brought maker Amgen Inc. $1.4 billion in sales in 2013, is a biologic used […] [read post]
20 Oct 2011, 11:46 pm
On September 28, Bayer won a dismissal of U.S. antitrust claims that were made against it by Sandoz Inc. [read post]
6 May 2013, 4:33 pm
On May 1, the US Court of Appeals for the Federal Circuit issued an interesting, yet controversial, ruling in Allergan Inc. v Sandoz Inc. et Al., examining obviousness in the context of a combination ophthalmic drug treatment. [read post]
9 Jan 2016, 6:00 pm by Lawrence B. Ebert
Sandoz Inc. that an "appellate court must apply a 'clear error,' not de novo, standard of review" to the evidentiary underpinnings of a district court's claim construction determination. [read post]
10 Jun 2010, 9:46 pm by Patent Docs
By James DeGiulio -- Endo Settles with Impax and Sandoz in Opana Patent Suits Endo Pharmaceuticals Inc. has settled patent infringement suits against Sandoz Inc. and Impax Laboratories Inc. over generic versions of painkiller Opana ER. [read post]
2 Jan 2015, 8:30 am
Indianapolis, Indiana - In conjunction with co-counsel, an Indiana patent attorney for Eli Lilly and Company of Indianapolis, Indiana sued in the Southern District of Indiana alleging infringement by Sandoz Inc. of Princeton, New Jersey of ALIMTA®, Patent No. 7,772,209, which was issued by the U.S. [read post]
3 Nov 2023, 7:15 am by David Hemming (Bristows)
The present case started as a claim for infringement brought by Astellas Pharma Inc (“Astellas”) against Teva and Sandoz (the “Defendants”). [read post]
25 Jan 2024, 8:25 pm by Patent Docs
Sandoz, Inc.) was that an inordinate proportion of claim construction decisions were overturned in whole or part. [read post]
7 Jul 2020, 9:15 am by Rebecca Tapscott
Sandoz, Inc., Sandoz International GMBH, Sandoz GMBH, holding that Sandoz failed to prove that the asserted claims were invalid for obviousness-type double patenting (ODP), failure to meet the written description requirement, and obviousness for lack of motivation to combine the prior art references. [read post]